Last reviewed · How we verify

NCT00280657

Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa

Completed Phase 3 Last updated 6 June 2023
What this trial tests

Phase 3 trial testing Valette in Acne Vulgaris in 1,326 participants. Completed in 21 May 2005.

Timeline
10 March 2004
Primary endpoint
21 May 2005
21 May 2005

Quick facts

Lead sponsorBayer
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment1,326
Start date10 March 2004
Primary completion21 May 2005
Estimated completion21 May 2005
Sites62 locations across Slovakia, Russia, Ukraine, Poland, Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Bayer — full company profile →

Who can join

Adults 16 to 45, female only, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine safety and efficacy of an oral contraceptive in treating acne papulopustulosa.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

Other Bayer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00280657.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing